Real-World Early Outcomes With Brexu-Cel in MCL Demonstrate Feasibility and Positive Efficacy

Despite its use in a population with broad characteristics and high-risk features, a real-world outcome analysis demonstrated brexucabtagene autoleucel’s feasibility and efficacy in those with mantle cell lymphoma.

An assessment of real-world outcomes with brexucabtagene autoleucel (brexu-cel; Tecartus) in patients with mantle cell lymphoma (MCL) indicated that the CAR T-cell therapy was both feasible and efficacious, despite being used in a population with a broad range of baseline characteristics and high-risk features.1

The median time to initial response was 30 days (range, 16-104) following treatment with brexu-cel, with a 30-day overall response rate (ORR) of 88% in an evaluable population of 92 patients, including a complete response (CR) rate of 66% and a partial response (PR) rate of 22%.

Notably, best ORR in the real-world study was 89%, which was comparable to the phase 2 ZUMA-2 trial (NCT02601313), which reported a rate of 93%.2 Additionally, 9% of patients had progressive disease and 1% had stable disease. One of 2 patients with stable disease at day 30 achieved a CR after a median of 64 days.

When responses were assessed by patient subgroup, investigators reported an ORR of 95% and CR rate of 87% in those with blastoid/pleomorphic morphology (n = 39); 87% and 71%, respectively, for those with a TP53 deletion or mutation (n = 31); 90% and 78% in those with a Ki67 percentage score of 50% of more (n = 50); 82% and 64% in those with a high score by the Simplified Mantle Cell Lymphoma international Prognostic Index (n = 11); and 86% and 57% for those with central nervous system (CNS) involvement (n = 7). Additionally, patients who were Burton tyrosine kinase (BTK) inhibitor naïve (n = 17) experienced an ORR of 94% and a CR rate of 88%, and those ineligible for the ZUMA-2 trial (n = 74­) had rates of 91% and 80%, respectively.

In terms of additional study findings, investigators reported that the median duration of response (DOR) had not been reached after a median follow-up of 6.7 months (range, 0.5-13.6). The 6-month DOR rate was 70% (95% CI, 57%-80%), which was found to be comparable with findings from ZUMA-2. Additionally, the median progression-free survival (PFS) and overall survival (OS) were not reached. The 6- and 12-month PFS rates were 66% (95% CI, 54%-75%) and 51% (95% CI, 37%-64%), respectively. Moreover, the 6- and 12-month OS rates were 81% (95% CI, 70%-88%) and 72% (95% CI, 57%-82%), respectively.

Eligibility criteria for the ZUMA-2 trial included having between 1 to 5 prior lines of therapy, including an anti-CD20 agent, anthracycline or bendamustine, and ibrutinib (Imbruvica) or acalabrutinib (Calquence); an ECOG performance status of 2 or lower; adequate blood counts, hepatic function, and renal function; and no significant comorbidities. Bridging therapies included corticosteroids, ibrutinib, and acalabrutinib.2

A total of 14 centers participated in the study, which included patients who underwent leukapheresis by June 2021 to manufacture brexu-cel. Investigators collected data relating to clinical characteristics, bridging therapy, adverse effects (AEs) following brexu-cel treatment, and outcomes following infusion.

One hundred and seven patients underwent leukapheresis, 12 of whom did not go on to receive an infusion due to manufacture failure (n = 6), organ dysfunction (n = 1), or death (n = 5). Ninety-five patients received a brexu-cel infusion.

Patients included in the analysis had a median age of 67 years (range, 34-89) and most were men (80%). Additionally, 57% of patients had a Ki-67 percentage score of 50% or more and 41% had blastoid/pleomorphic morphology (41%). Forty-four percent of patients had a TP53 mutation or deletion and 29% had a complex karyotype.

Treatment-related reasons for ZUMA-2 ineligibility included receiving over 5 lines of therapy (13%), not previously receiving a BTK inhibitor (18%), or not receiving a previous CD20 agent, anthracycline, or bendamustine (14%). Other reasons for ineligibility included having an absolute neutrophil count of less than 1000/µL (8%), an absolute lymphocyte count of less than 100/µL (1%), a platelet count of less than 75,000/µL (5%), a creatinine level of more than 1.5 mg/dL (8%), or creatinine clearance of less than 60 mL/minute (20%). Notably, 78% of patients included in the analysis would not have met inclusion criteria for the ZUMA-2 trial.

In total, 67% of patients underwent bridging therapy, with a median time from leukapheresis to lymphodepleting chemotherapy of 23 days. The median time from lymphodepleting chemotherapy to CAR T-cell infusion was 5 days.

Among those treated, 91% developed cytokine release syndrome (CRS) and 60% developed immune effector cell–associated neurotoxicity syndrome (ICANS). Eight percent of all CRS events and 35% of ICANS events were grade 3 or 4 in severity. The incidence of CRS and ICANS were comparable with events that were observed in the ZUMA-2 trial. Median time to onset of events was 4 and 6 days, respectively, and a median duration of 5 and 6 days. The events were most commonly managed with tocilizumab (Actemra; 79%), steroids (69%), which appeared to be more frequent than in ZUMA-2. Twenty-one percent of patients were admitted to intensive care for a median of 3 days, with 11% needing vasopressors, 4% needing mechanical ventilation, and 3% needing dialysis (3%).

These findings were presented at the 2022 Tandem Meeting.


  1. Munoz J, Wang Y, Jain P, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US lymphoma CAR T consortium. Presented at: 2022 Transplantation & Cellular Therapy Meetings; Salt Lake City, UT; April 23-26, 2022. Abstract 265.
  2. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347
Related Videos
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Amitkumar Mehta, MD, discusses overall response rates from the CITADEL-205 study looking at parsaclisib for patients with relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.
Related Content